Roche and Biogen Idec are discontinuing development of ocrelizumab in rheumatoid arthritis (RA) following analysis of the safety efficacy results. The companies concluded that the risk/benefit profile was not favorable in RA taking into account currently available treatment options. Ocrelizumab is also being evaluated in a Phase II study for relapsing remitting multiple sclerosis (RRMS). The ocrelizumab RA program included four Phase III studies (SCRIPT, FILM, FEATURE, and STAGE). Analysis in...